FLUDARA LYOPHILIZED IV INJECTION

L01BB05(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-only (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol 21679-14-1N 657237 4802 DB01073Y 571392Y P2K93U8740 D01907Y CHEBI:63599N ChEMBL1568Y DTXSID2023060 Interactive image Fc1nc(c2ncn(c2n1)[C@@H]3O[C@@H]([C@@H](O)[C@@H]3O)CO)N InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1YKey:HBUBKKRHXORPQB-FJFJXFQQSA-NY Fludarabineis a purine analogue and antineoplastic agent.‍‍‍‍‍‍​​​‍​​​​​​ It is generally used as its 5-O-phosphorylated form known as fludarabine phosphate, sold under the brand nameFludaraamong others. It is achemotherapy medicationused in the treatment ofleukemiaandlymphoma.These includechronic lymphocytic leukemia,non-Hodgkin's lymphoma,acute myeloid leukemia, andacute lymphocytic leukemia.It is given byinjection into a veinor by mouth. Common side effects include nausea,diarrhea, fever, rash, shortness of breath, numbness, vision changes, and feeling tired.Severe side effects includebrain dysfunction,low blood cell counts, andlung inflammation.Use inpregnancywill likely result in harm to the fetus.Fludarabine is in thepurine analogfamily of medications and works by interfering with theduplication of DNA. Fludarabine was approved for medical use in the United States in 1991.It is on theWorld Health Organization's List of Essential Medicines.